Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice
Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors. In this st...
Gespeichert in:
| Veröffentlicht in: | Investigational new drugs 2019-10, Vol.37 (5), p.961 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 961 |
| container_title | Investigational new drugs |
| container_volume | 37 |
| creator | Chang, Ya-Jen Ho, Chung-Li Cheng, Kai-Hung Kuo, Wan-I Lee, Wan-Chi Lan, Keng-Li Chang, Chih-Hsien |
| description | Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors. In this study, cetuximab with a combination of radiotherapy nuclear
Re achieved better therapeutic effect on lung cancer. Methods
Re-cetuximab administered by the i.v. route in human NCI-H292 lung tumor-bearing mice was investigated. NanoSPECT/CT images were taken to evaluate the distribution and tumor targeting of
Re-cetuximab in mice. The anti-tumor effect of
Re-cetuximab was assessed by the tumor growth inhibition, survival ratio. Results For nanoSPECT/CT imaging, a significant uptake in tumor was observed at 24 and 48 h following the injection of
Re-cetuximab. The anti-tumor effect of
Re-cetuximab was assessed by tumor growth inhibition and the survival ratio. The tumor-bearing mice treated with
Re-cetuximab showed a better mean tumor growth inhibition rate (MGI = 0.049) and longer median survival time and lifespan (62.50 d; 70.07%) than those treated with
Re-perrhenate and cetuximab only by single injection. A synergistic effect of tumor growth inhibition was observed with the combination index exceeding one for
Re-cetuximab (CI = 6.135 and 9.276). Conclusion The tumor targeting and localization of 188Re-cetuximab were confirmed in this study. Synergistic therapeutic efficacy was demonstrated for the radioimmunotherapy of
Re-cetuximab. The results of this study reveal the potential advantage and benefit obtained from
Re-cetuximab for diagnosis and therapy of oncology applications in the future. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_30612308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30612308</sourcerecordid><originalsourceid>FETCH-pubmed_primary_306123083</originalsourceid><addsrcrecordid>eNqFjs1qAjEURoMg_rR9BbkP0EBmYsdxW2mxGxfiXu5Mrs5Vkwz5gUpfXhd27erjwOHwDcSk-Fhoqap5NRbTGE9KKb1czEdirFVVlFrVE_H3yd5wTIGbnNi7d-g7DBZbf2ZHidsI6AwENOzZ2ux86ihgfwV_gKKuYUuypZR_2WID7GCz-pHrcllCly06uGR3hJStD7IhDHwnlw2B5ZZexfCAl0hvj30Rs--v3Wot-9xYMvs-3KPhuv9_q58KNx4rS0o</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chang, Ya-Jen ; Ho, Chung-Li ; Cheng, Kai-Hung ; Kuo, Wan-I ; Lee, Wan-Chi ; Lan, Keng-Li ; Chang, Chih-Hsien</creator><creatorcontrib>Chang, Ya-Jen ; Ho, Chung-Li ; Cheng, Kai-Hung ; Kuo, Wan-I ; Lee, Wan-Chi ; Lan, Keng-Li ; Chang, Chih-Hsien</creatorcontrib><description>Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors. In this study, cetuximab with a combination of radiotherapy nuclear
Re achieved better therapeutic effect on lung cancer. Methods
Re-cetuximab administered by the i.v. route in human NCI-H292 lung tumor-bearing mice was investigated. NanoSPECT/CT images were taken to evaluate the distribution and tumor targeting of
Re-cetuximab in mice. The anti-tumor effect of
Re-cetuximab was assessed by the tumor growth inhibition, survival ratio. Results For nanoSPECT/CT imaging, a significant uptake in tumor was observed at 24 and 48 h following the injection of
Re-cetuximab. The anti-tumor effect of
Re-cetuximab was assessed by tumor growth inhibition and the survival ratio. The tumor-bearing mice treated with
Re-cetuximab showed a better mean tumor growth inhibition rate (MGI = 0.049) and longer median survival time and lifespan (62.50 d; 70.07%) than those treated with
Re-perrhenate and cetuximab only by single injection. A synergistic effect of tumor growth inhibition was observed with the combination index exceeding one for
Re-cetuximab (CI = 6.135 and 9.276). Conclusion The tumor targeting and localization of 188Re-cetuximab were confirmed in this study. Synergistic therapeutic efficacy was demonstrated for the radioimmunotherapy of
Re-cetuximab. The results of this study reveal the potential advantage and benefit obtained from
Re-cetuximab for diagnosis and therapy of oncology applications in the future.</description><identifier>EISSN: 1573-0646</identifier><identifier>PMID: 30612308</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacokinetics ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents, Immunological - pharmacokinetics ; Antineoplastic Agents, Immunological - therapeutic use ; Apoptosis ; Cell Proliferation ; Cetuximab - pharmacokinetics ; Cetuximab - therapeutic use ; Humans ; Lung Neoplasms - immunology ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Mice ; Mice, Nude ; Radioimmunotherapy - methods ; Radioisotopes - pharmacokinetics ; Radioisotopes - therapeutic use ; Rhenium - pharmacokinetics ; Rhenium - therapeutic use ; Tissue Distribution ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays</subject><ispartof>Investigational new drugs, 2019-10, Vol.37 (5), p.961</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30612308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Ya-Jen</creatorcontrib><creatorcontrib>Ho, Chung-Li</creatorcontrib><creatorcontrib>Cheng, Kai-Hung</creatorcontrib><creatorcontrib>Kuo, Wan-I</creatorcontrib><creatorcontrib>Lee, Wan-Chi</creatorcontrib><creatorcontrib>Lan, Keng-Li</creatorcontrib><creatorcontrib>Chang, Chih-Hsien</creatorcontrib><title>Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors. In this study, cetuximab with a combination of radiotherapy nuclear
Re achieved better therapeutic effect on lung cancer. Methods
Re-cetuximab administered by the i.v. route in human NCI-H292 lung tumor-bearing mice was investigated. NanoSPECT/CT images were taken to evaluate the distribution and tumor targeting of
Re-cetuximab in mice. The anti-tumor effect of
Re-cetuximab was assessed by the tumor growth inhibition, survival ratio. Results For nanoSPECT/CT imaging, a significant uptake in tumor was observed at 24 and 48 h following the injection of
Re-cetuximab. The anti-tumor effect of
Re-cetuximab was assessed by tumor growth inhibition and the survival ratio. The tumor-bearing mice treated with
Re-cetuximab showed a better mean tumor growth inhibition rate (MGI = 0.049) and longer median survival time and lifespan (62.50 d; 70.07%) than those treated with
Re-perrhenate and cetuximab only by single injection. A synergistic effect of tumor growth inhibition was observed with the combination index exceeding one for
Re-cetuximab (CI = 6.135 and 9.276). Conclusion The tumor targeting and localization of 188Re-cetuximab were confirmed in this study. Synergistic therapeutic efficacy was demonstrated for the radioimmunotherapy of
Re-cetuximab. The results of this study reveal the potential advantage and benefit obtained from
Re-cetuximab for diagnosis and therapy of oncology applications in the future.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents, Immunological - pharmacokinetics</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Apoptosis</subject><subject>Cell Proliferation</subject><subject>Cetuximab - pharmacokinetics</subject><subject>Cetuximab - therapeutic use</subject><subject>Humans</subject><subject>Lung Neoplasms - immunology</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Radioimmunotherapy - methods</subject><subject>Radioisotopes - pharmacokinetics</subject><subject>Radioisotopes - therapeutic use</subject><subject>Rhenium - pharmacokinetics</subject><subject>Rhenium - therapeutic use</subject><subject>Tissue Distribution</subject><subject>Tumor Cells, Cultured</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFjs1qAjEURoMg_rR9BbkP0EBmYsdxW2mxGxfiXu5Mrs5Vkwz5gUpfXhd27erjwOHwDcSk-Fhoqap5NRbTGE9KKb1czEdirFVVlFrVE_H3yd5wTIGbnNi7d-g7DBZbf2ZHidsI6AwENOzZ2ux86ihgfwV_gKKuYUuypZR_2WID7GCz-pHrcllCly06uGR3hJStD7IhDHwnlw2B5ZZexfCAl0hvj30Rs--v3Wot-9xYMvs-3KPhuv9_q58KNx4rS0o</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Chang, Ya-Jen</creator><creator>Ho, Chung-Li</creator><creator>Cheng, Kai-Hung</creator><creator>Kuo, Wan-I</creator><creator>Lee, Wan-Chi</creator><creator>Lan, Keng-Li</creator><creator>Chang, Chih-Hsien</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201910</creationdate><title>Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice</title><author>Chang, Ya-Jen ; Ho, Chung-Li ; Cheng, Kai-Hung ; Kuo, Wan-I ; Lee, Wan-Chi ; Lan, Keng-Li ; Chang, Chih-Hsien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_306123083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents, Immunological - pharmacokinetics</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Apoptosis</topic><topic>Cell Proliferation</topic><topic>Cetuximab - pharmacokinetics</topic><topic>Cetuximab - therapeutic use</topic><topic>Humans</topic><topic>Lung Neoplasms - immunology</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Radioimmunotherapy - methods</topic><topic>Radioisotopes - pharmacokinetics</topic><topic>Radioisotopes - therapeutic use</topic><topic>Rhenium - pharmacokinetics</topic><topic>Rhenium - therapeutic use</topic><topic>Tissue Distribution</topic><topic>Tumor Cells, Cultured</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Ya-Jen</creatorcontrib><creatorcontrib>Ho, Chung-Li</creatorcontrib><creatorcontrib>Cheng, Kai-Hung</creatorcontrib><creatorcontrib>Kuo, Wan-I</creatorcontrib><creatorcontrib>Lee, Wan-Chi</creatorcontrib><creatorcontrib>Lan, Keng-Li</creatorcontrib><creatorcontrib>Chang, Chih-Hsien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Ya-Jen</au><au>Ho, Chung-Li</au><au>Cheng, Kai-Hung</au><au>Kuo, Wan-I</au><au>Lee, Wan-Chi</au><au>Lan, Keng-Li</au><au>Chang, Chih-Hsien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>2019-10</date><risdate>2019</risdate><volume>37</volume><issue>5</issue><spage>961</spage><pages>961-</pages><eissn>1573-0646</eissn><abstract>Background Cetuximab is a fully humanized IgG1 subclass monoclonal that binds specifically to the human epidermal growth factor receptor (EGFR). Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, such as colon, rectum and lung tumors. In this study, cetuximab with a combination of radiotherapy nuclear
Re achieved better therapeutic effect on lung cancer. Methods
Re-cetuximab administered by the i.v. route in human NCI-H292 lung tumor-bearing mice was investigated. NanoSPECT/CT images were taken to evaluate the distribution and tumor targeting of
Re-cetuximab in mice. The anti-tumor effect of
Re-cetuximab was assessed by the tumor growth inhibition, survival ratio. Results For nanoSPECT/CT imaging, a significant uptake in tumor was observed at 24 and 48 h following the injection of
Re-cetuximab. The anti-tumor effect of
Re-cetuximab was assessed by tumor growth inhibition and the survival ratio. The tumor-bearing mice treated with
Re-cetuximab showed a better mean tumor growth inhibition rate (MGI = 0.049) and longer median survival time and lifespan (62.50 d; 70.07%) than those treated with
Re-perrhenate and cetuximab only by single injection. A synergistic effect of tumor growth inhibition was observed with the combination index exceeding one for
Re-cetuximab (CI = 6.135 and 9.276). Conclusion The tumor targeting and localization of 188Re-cetuximab were confirmed in this study. Synergistic therapeutic efficacy was demonstrated for the radioimmunotherapy of
Re-cetuximab. The results of this study reveal the potential advantage and benefit obtained from
Re-cetuximab for diagnosis and therapy of oncology applications in the future.</abstract><cop>United States</cop><pmid>30612308</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1573-0646 |
| ispartof | Investigational new drugs, 2019-10, Vol.37 (5), p.961 |
| issn | 1573-0646 |
| language | eng |
| recordid | cdi_pubmed_primary_30612308 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - pharmacokinetics Antineoplastic Agents, Immunological - therapeutic use Apoptosis Cell Proliferation Cetuximab - pharmacokinetics Cetuximab - therapeutic use Humans Lung Neoplasms - immunology Lung Neoplasms - metabolism Lung Neoplasms - pathology Lung Neoplasms - therapy Male Mice Mice, Nude Radioimmunotherapy - methods Radioisotopes - pharmacokinetics Radioisotopes - therapeutic use Rhenium - pharmacokinetics Rhenium - therapeutic use Tissue Distribution Tumor Cells, Cultured Xenograft Model Antitumor Assays |
| title | Biodistribution, pharmacokinetics and radioimmunotherapy of 188 Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biodistribution,%20pharmacokinetics%20and%20radioimmunotherapy%20of%20188%20Re-cetuximab%20in%20NCI-H292%20human%20lung%20tumor-bearing%20nude%20mice&rft.jtitle=Investigational%20new%20drugs&rft.au=Chang,%20Ya-Jen&rft.date=2019-10&rft.volume=37&rft.issue=5&rft.spage=961&rft.pages=961-&rft.eissn=1573-0646&rft_id=info:doi/&rft_dat=%3Cpubmed%3E30612308%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30612308&rfr_iscdi=true |